ReShape Lifesciences - רווח החברה לפני מסים, ריבית ופחת RSLS

ReShape Lifesciences (RSLS) is expanding its business in the supply of bariatric consumables to create a recurring revenue stream. Changes in EBITDA_Co visualize this trajectory, with the current figure standing at . Lap-Band safety systems ensure stable pricing within the weight loss niche. The company is currently transforming its sales into comprehensive programs to mitigate pressure from new pharmaceutical drugs.

Amid competition from GLP-1 drugs, ReShape Lifesciences is optimizing its surgical business, as reflected in its EBITDA dynamics. The current value of represents the operating cash flow before depreciation, excluding non-cash charges to assess the company's actual ability to generate cash, which is critical for confirming financial stability during the period of asset restructuring.